[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hernia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hernia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,51,79,110,139,175,198,223,252,277],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100613507","image-guided-herniorrhaphy-study-100613507",false,"NCT07267494","Image-Guided Herniorrhaphy Study","Image-guided Herniorrhaphy Safety and Efficacy Pilot","Inclusion Criteria:\n\n* English-speaking adult with reducible hernia(s) or diastasis smaller than approximately 8 cm seeking treatment for their hernia but not able or willing to undergo traditional surgery (open, laparoscopic, or robotic)\n* Patient must be willing to undergo a novel 30- to 60-minute image-guided needle-based procedure\n\nExclusion Criteria:\n\n* Children, prisoners, and pregnant women (possibly requiring a pregnancy test on the day of the procedure)\n* Patients with a known reaction to local anesthetic or sedation medications or the suture material to be used\n* Patients with irreducible hernias\n* Patients with herniation not visible by ultrasound or CT\n* Patients that do not fit the diameter of a CT gantry or the weight limit of the procedural CT table\n* Patients without insurance or not willing to pay out-of-pocket for the study procedure","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot clinical study will evaluate the safety and effectiveness of a new image-guided, needle-based approach for repairing abdominal or groin hernias in adults who are unable or unwilling to undergo traditional open or laparoscopic surgery. The technique uses ultrasound and, when needed, CT imaging to guide a hollow needle preloaded with barbed suture through the skin to close the hernia defect without large incisions or general anesthesia. Each participant will undergo one image-guided procedure and will be followed for eight months to assess complications and changes in hernia-related quality of life. Approximately thirty participants will be enrolled. The study aims to determine whether this minimally invasive approach is safe, feasible, and capable of improving hernia symptoms enough to justify a larger clinical trial",[26,27,28,29,30,31],"Hernia","Hernia Abdominal Wall","Ventral Hernia","Inguinal Hernia","Hiatal Hernia","Diastasis Recti",[33,34,35,36,37],"Image-guided herniorrhaphy","hernia","pilot study","quality of life","safety and feasability","NOT_YET_RECRUITING","2026-06-12",{"date":41,"type":42},"2026-06-16","ACTUAL",{"date":44,"type":20},"2026-12-01",{"date":46,"type":20},"2029-05-01",{"name":48,"class":49},"University of California, Davis","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100614311","atraumatic-laparoscopic-hernia-repair-clinical-investigation-to-evaluate-the-safety-and-performance-of-the-eclipsium-system-for-mesh-fixation-ide-100614311","NCT07277946","AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE","UNITE","Inclusion Criteria:\n\n1. Patient is 22 years old or older.\n2. Patient is willing and able to provide a signed Patient Informed Consent Form.\n3. Patient has a single midline primary ventral, umbilical, or incisional hernia;\n\n   a.Hernia Size is 1 -5 cm in diameter (to be confirmed intraoperatively).\n4. Patient is scheduled for a laparoscopic IPOM hernia repair.\n5. Hernia can be successfully repaired with a single polyester or polypropylene composite mesh with biodegradable coating with at least a 5 cm overlap of the mesh on all sides of the defect (to be confirmed intraoperatively).\n6. Female patients must:\n\n   1. Have a negative urine pregnancy test within 3 days before surgery and agree to consistently use an effective method of contraception through completion of study participation.\n\n      OR\n   2. Have reached menopause (no menses for 1 year). OR\n   3. Have undergone hysterectomy, bilateral oophorectomy, or tubal ligation.\n7. Patient is willing and able to follow the study instructions including completion of study procedures, assessments, and visits.\n\nExclusion Criteria:\n\n1. Patient has a known or suspected hypersensitivity to the constituent polymer of the investigational device, comparator device, mesh, or other surgical products (e.g., sutures).\n2. Patient is taking systemic photosensitivity pharmaceutical products at time of informed consent.\n3. Patient has a BMI \\> 40.\n4. Patient is a current smoker, defined as self-reporting smoking more than 1 cigarette per day.\n5. Patient's hernia is recurrent and\u002For the patient has a previous midline primary ventral, umbilical, or incisional hernia repair with mesh implantation.\n6. Patient has a life expectancy less than 1 year, in the opinion of the Investigator.\n7. Patient is unwilling or unable to follow postoperative instructions.\n8. Patient is taking systemic immunosuppressive medications, systemic steroids, or chemotherapy at the time of informed consent.\n9. Patient is pregnant, plans to become pregnant during the study period, or is breastfeeding.\n10. Patient has a diagnosis of Type 1 Diabetes Mellitus.\n11. Patient has uncontrolled Type 2 Diabetes Mellitus (HbA1C ≥ 7.0 within 3 months preceding study enrolment).\n12. Patient is currently participating in an investigational drug or device study that has not completed the primary outcome or that clinically interferes with this clinical study's outcome (Note: Studies requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational studies).\n13. Patient has more than one hernia defect (single hernia defect between 1-5 cm in diameter from outer edged to outer edge to be confirmed intraoperatively).\n14. Patient has areas of weakness, independent from the hernia to be treated, in the area covered by mesh or mesh-adjacent tissues (to be confirmed intraoperatively).\n15. Patient with a complex hernia, likely not eligible for laparoscopic repair, as determined by the Investigator (ex. small bowel resection; to be confirmed intraoperatively).\n16. Patient is scheduled for an additional surgery within 6 weeks after the index-procedure or has undergone surgery within 90 days before the index-procedure.\n17. Patient has severe chronic obstructive pulmonary disease.\n18. Patient has an ongoing infection (e.g. elevated temperature, elevated white blood count).\n19. In the opinion of the Investigator, the patient is not a suitable candidate for the clinical investigation.","22 Years",{"count":60,"type":20},240,[23],"The primary purpose of this clinical trial is to assess the safety and performance of the ECLIPSIUM device in securing mesh during ventral hernia repair. The study will evaluate whether ECLIPSIUM, a bioresorbable polymer-based fixation device, is effective in reducing the risk of hernia recurrence when compared with bioresorbable tacks. This information will support understanding of ECLIPSIUM's potential clinical benefits in ventral hernia repair.",[26],[65,26,66],"Ventral Hernia Repair","Hernia Repair","RECRUITING","2026-06-08",{"date":70,"type":42},"2026-06-09",{"date":72,"type":42},"2026-05-14",{"date":74,"type":20},"2026-12",{"name":76,"class":77},"Tissium","INDUSTRY",12,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":86,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":99,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":50},"100605719","prospective-registry-for-long-term-outcomes-following-feto-in-severe-left-and-right-cdh-100605719","NCT07166172","Prospective Registry for Long-term Outcomes Following FETO in Severe Left and Right CDH","North American Fetal Therapy Network Prospective Registry for Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in Severe Left and Right Congenital Diaphragmatic Hernia","Inclusion Criteria:\n\n* Pregnant women age 18 years and older\n* Singleton pregnancy\n* Normal Karyotype, chromosomal microanalysis (CMA) with non-pathologic variants, whole exome sequencing (WES) or whole genome sequencing (WGS). Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is \\> 26 weeks gestation.\n* Gestational age at enrollment is prior to 29 weeks + 6 days gestation.\n* Intrathoracic liver herniation:\n\n  * Isolated left CDH with o\u002Fe LHR \\\u003C 30% at enrollment (18wks + 0 days to 29wks + 5 days gestation).\n  * Isolated right CDH with o\u002Fe LHR ≤ 45% at enrollment (18wks + 0 days to 29wks + 5 days gestation).\n* Cervical length by transvaginal ultrasound ≥ 20 mm within 24 hours prior to FETO procedure.\n* Patient meets psychosocial criteria.\n* Informed consent understood.\n\nExclusion Criteria:\n\n* Patient \\\u003C 18 years of age\n* Multi-fetal pregnancy\n* History of natural rubber latex allergy\n* Preterm labor, cervix shortened (\\\u003C20 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa.\n* Psychosocial ineligibility, precluding consent:\n\n  1. Inability to reside within 30 minutes of Johns Hopkins Hospital Center for Fetal Therapy.\n  2. The patient does not have a support person (e.g., spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Johns Hopkins Hospital Center for Fetal Therapy.\n* Bilateral CDH, isolated left sided CDH with O\u002FE LHR ≥ 30% (18wks + 0 days to 29wks + 5 days gestation), isolated right sided CDH with O\u002FE LHR \\> 45% (18wks + 0 days to 29wks + 5 days gestation), as determined by ultrasound.\n* No liver herniation into thoracic cavity.\n* Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram at the fetal treatment center. Exclude chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., CDH and congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns).\n* Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy.\n* History of incompetent cervix with or without cerclage.\n* Placental abnormalities (previa, abruption, accreta) known at time of enrollment\n* Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy.\n* Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment.\n* Uterine anomalies such as large or multiple fibroids or Mullerian duct abnormality.\n* There is no safe or technically feasible fetoscopic approach to balloon placement.\n* Participation in another intervention study that influences maternal and fetal morbidity and mortality. or participation in this trial in a previous pregnancy.","FEMALE",{"count":88,"type":20},80,[23],"This registry study aims to confirm that FETO increases neonatal survival to discharge and reduces long-term morbidity in fetuses with isolated left CDH and o\u002Fe LHR \\\u003C 30%, or isolated right CDH and o\u002Fe LHR ≤ 45%, compared to those receiving standard care. This prospective registry plans to enroll 80 pregnant women (40 treatment\u002F40 control) with fetuses diagnosed with isolated CDH, and the children will be followed for up to 24 months.",[92,93,94,95,96,26,97,98],"Congenital Diaphragmatic Hernia","Congenital Abnormalities","Neonatal Diseases and Abnormalities","Hernia, DIaphragmatic, Congenital","Internal Hernia","Pathological Conditions, Anatomical","Pathological Conditions, Signs and Symptoms",[100],"Fetoscopic Endoluminal Tracheal Occlusion","2026-04-20",{"date":103,"type":42},"2026-04-23",{"date":105,"type":42},"2025-06-23",{"date":107,"type":20},"2031-12-01",{"name":109,"class":49},"Johns Hopkins University",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100617269","preoptimisation-in-ventral-hernia-surgery-100617269","NCT07316426","Preoptimisation in Ventral Hernia Surgery","Preoptimisation in Ventral Hernia Surgery- a Randomised Trial","PreOpt","Inclusion Criteria:\n\n* Patients with a ventral hernia with a defect width of at least 4 cm.\n* Symptom burden related to the hernia sufficient to justify surgical intervention.\n* Age ≥ 18 years.\n\nExclusion Criteria:\n\n* Expected survival of less than three years.\n* Inability to comprehend oral and written information or to provide informed consent.\n* Acute complication of the hernia requiring emergency surgical intervention.\n* General condition characterised by severe limitations in physical functional capacity.",{"count":119,"type":20},130,[23],"The study is a multicentre, single-blinded, randomised controlled trial. Ventral hernia patients with an aperture width between four and eight centimetres are randomised to either participation in a multimodal preoptimisation programme, including interventions to increase physical activity, promote weight loss, and optimise the treatment of comorbidities, or to surgery without structured preoptimisation. The primary endpoint is complications at three months postoperatively. During surgery, biopsies of skin, muscle, and fascia will be collected, along with pre- and postoperative blood samples, to analyse the molecular effects of preoptimisation, particularly in relation to collagen metabolism.",[26,123,124,125],"Hernia, Ventral","Hernia Incisional","Hernia, Umbilical",[127,128],"preoptimisation","prehabilitation","2025-12-18",{"date":131,"type":42},"2026-01-05",{"date":133,"type":42},"2025-09-22",{"date":135,"type":20},"2029-09-01",{"name":137,"class":49},"Umeå University",5,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":151,"conditions":152,"keywords":157,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":50},"100609884","phase-4-preoperative-botox-injection-for-large-ventral-hernia-repair-100609884","NCT07220382","Preoperative BOTOX® Injection for Large Ventral Hernia Repair","PREoperative Targeted OnabotulinumtoXina Injection for Abdominal Wall Reconstruction: A Randomized, Double-Blind, Placebo-Controlled Trial","PRETOX","Inclusion Criteria:\n\n* Adult (greater than or equal to 18 years of age)\n* Candidate for elective open repair of ventral hernia\n* Preoperative imaging demonstrating either:\n* ventral hernia defect width of at lest 15 cm; AND\u002FOR,\n* Tanaka volume ratio of at least 25%\n* Planned elective hernia repair in an open fashion via a midline laparotomy with posterior component separation and transversus abdominis release\n\nExclusion Criteria:\n\n* Emergent cases\n* Pregnancy and\u002For breastfeeding at time of intramuscular injection\n* Inability to provide informed consent\n* Inability to receive either study intervention (i.e. allergy to local anesthetics utilized for intervention administration, allergy and\u002For contraindication to any botulinum toxin, inability to attend outpatient administration of study intervention, inability to conform to safety check schedule)\n* Known congenital or acquired neuromuscular disorder\n* Presence of stoma\n* Current infection at time of intramuscular injection\n* Flank hernias s defined by EHS L1-L4\n* BMI \\> 45 kg\u002Fm\\^2\n* Diaphragmatic hemiparesis or chronic obstructive pulmonary disease (COPD) with chronic oxygen dependence",{"count":148,"type":20},188,[150],"PHASE4","This study is for adults who need open surgery to repair a very large abdominal (ventral) hernia. This study tests whether a one-time, image-guided injection of a medicine commonly known as \"BOTOX®\" (onabotulinumtoxinA) into the side abdominal muscles 3-7 weeks before surgery helps surgeons close the abdominal wall fully at the end of the operation. Closing the muscle and tissue layers (\"primary fascial closure\") is linked to fewer problems after surgery and better quality of life.\n\nParticipants will be randomly assigned (like a coin flip) to receive either the BOTOX® medicine or a saltwater (placebo) injection. Neither patients nor the care team will know which one was given. All participants will still have their planned hernia repair in the standard way that we repair patients who are not part of the study. The study will track whether the abdomen can be closed without leaving a gap, and investigators will also look at recovery, complications, time in the ICU or on a ventilator, length of stay, pain, and quality-of-life scores. Most information will be collected during participants' hospital stay, but the investigators will continue to see how participants are doing up to 2 years after surgery. Short phone check-ins will occur before surgery, and after surgery follow-up happens around 30 days, 90 days, 1 year, and 2 years.\n\nPossible risks from the injection include temporary muscle weakness, trouble swallowing or breathing, pain or infection at the injection site, and (if CT is used for guidance) a small amount of radiation exposure. Surgery itself carries the usual risks (pain, bleeding, wound problems). Benefits are not guaranteed, but the injection may make closure easier and recovery smoother. About 188 people will take part at Cleveland Clinic.",[27,153,154,155,156,26,124],"Botox Injection","Hernia Incisional Ventral","Hernia Repair With Compartment Syndrome","Hernia Surgery",[158,28,159,160,161,162,163,164,165],"BOTOX","Abdominal Wall Reconstruction","OnabotulinumtoxinA","Preoperative BOTOX","Primary Fascial Closure","Fascial Bridging","Transversus Abdominis Release","Posterior Component Separation","2025-11-18",{"date":168,"type":42},"2025-11-21",{"date":170,"type":42},"2025-11-03",{"date":172,"type":20},"2029-12-15",{"name":174,"class":49},"The Cleveland Clinic",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":50},"100269049","laparoscopic-groin-hernia-repair-by-a-3d-endolap-visible-mesh-with-or-without-liquiband-fix-8-mesh-fixation-100269049","NCT02781870","Laparoscopic Groin Hernia Repair by a 3D ENDOLAP Visible Mesh With or Without LiquiBand Fix 8 Mesh Fixation","Randomized Single-center Study on Laparoscopic Groin Hernia Repair by a 3D ENDOLAP Visible With and Without LiquiBand Fix 8 Mesh Fixation","Inclusion Criteria:\n\n* adult patients presenting with primary unilateral inguinal hernia\n* patients planed for a laparoscopic repair\n\nExclusion Criteria:\n\n* Age below 18 years\n* recurrent or incarcerated hernias\n* open hernia repair and bilateral hernias\n* concomitant repair of another kind of abdominal hernia\n* combined surgical procedures\n* no informed consent\n* pregnant women\n* ASA score 4 or more\n* contra-indications for MRI scans.","80 Years",{"count":184,"type":20},100,[23],"This study aims to visualize the implanted mesh in vivo by MRI in 20 patients at 1 month and 12 months post-operatively. Moreover, we want to evaluate the safety and efficiency of non-penetration mesh fixation techniques using pre-designed ENDOLAP 3D visible mesh placement versus mesh fixation using a synthetic LiquiBand Fix 8 glue for laparoscopic treatment of groin hernias.\n\nA total of 100 male and female patients will be entered in the trial in Maria Middelares Ghent, for which an inclusion period of 24 months is anticipated. Four surgeons of the department of surgery will screen all eligible consecutive patients for inclusion in the study. They will inform all patients about the surgery and the follow-up with MRI scan thereafter.",[26,188],"Recurrence","2025-04-10",{"date":191,"type":42},"2025-04-11",{"date":193,"type":42},"2016-05-09",{"date":195,"type":20},"2027-08",{"name":197,"class":49},"Algemeen Ziekenhuis Maria Middelares",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":50},"100576780","enhanced-recovery-after-urologic-surgery-100576780","NCT06789744","Enhanced Recovery After Urologic Surgery","Enhanced Recovery After Urologic Surgery: a Prospective Observational Study Comparing Regional with Conventional Anesthetic Techniques","Inclusion Criteria:\n\n* any age.\n* American Society of Anesthesiologists (ASA) physical status classification of I-III.\n* undergo urological surgery.\n* receive one of the following analgesic techniques: epidural analgesia (EA), paravertebral block (PVB), transversus abdominis plane (TAP) block, intravenous patient-controlled analgesia (PCA), or intrathecal morphine.\n* provided voluntary informed consent.\n\nExclusion Criteria:\n\n* a bleeding disorder or coagulopathy.\n* infection at the intended puncture site or systemic infection.\n* a known allergy to local anesthetics.\n* spinal deformity or spinal injury.\n* a psychiatric disorder that could impair their ability to cooperate with the study protocol.\n* pregnant or breastfeeding.\n* severe cardiovascular or pulmonary dysfunction.\n* chronic opioid use (defined as \\>1 month) at high doses.",{"count":206,"type":20},150,[23],"This clinical trial aims to investigate the analgesic efficacy of several perioperative pain management strategies-specifically, epidural analgesia, paravertebral blockade, transversus abdominis plane (TAP) block, intravenous patient-controlled analgesia (PCA), and intrathecal morphine-in patients undergoing a range of urological procedures. These procedures include pediatric circumcision, hydrocelectomy, inguinal hernia repair, renal cyst excision, and transurethral resection of the prostate. The trial will also evaluate the safety profiles of two specific local anesthetics, liposomal bupivacaine and ropivacaine. The primary research question is whether these different analgesic techniques reduce postoperative opioid requirements in patients undergoing urological surgery. A secondary question explores the adverse events associated with the use of liposomal bupivacaine and ropivacaine in this population.\n\nParticipants will be:\n\nUrological surgery patients undergoing one of the aforementioned procedures. These participants will be randomized to receive one of the following pain management modalities: epidural analgesia, paravertebral blockade, TAP block, intravenous PCA, or intrathecal morphine. Patient assessments will be conducted in the post-anesthesia care unit (PACU) and at 2, 6, 12, and 24 hours postoperatively. Outcome measures will include: Numeric Rating Scale (NRS) pain scores, total postoperative analgesic consumption, recovery status, patient satisfaction, and time to return of bowel function.",[210,211,26,212,213],"Circumcision","Hydrocelectomy","Renal Cyst","Prostate","2025-01-22",{"date":216,"type":42},"2025-01-24",{"date":218,"type":20},"2025-02-01",{"date":220,"type":20},"2025-05-20",{"name":222,"class":49},"Xiaguang Duan",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100563194","phase-4-intravenous-tramadol-and-magnesium-sulphate-for-prevention-of-shivering-100563194","NCT06612996","Intravenous Tramadol and Magnesium Sulphate for Prevention of Shivering","Comparative Study Between Intravenous Tramadol and Magnesium Sulphate for Prevention of Shivering Post Intrathecal Anesthesia a Randomized Clinical Study","Inclusion Criteria:\n\n\\- American Society of Anesthesiologists (ASA) I and II physical status undergoing an elective surgery under spinal anesthesia.\n\nExclusion Criteria:\n\n* history of uncontrolled comorbidities, cardiac, respiratory, renal or hepatic disease, patients who had allergy to any medication in the study, contraindications to spinal anesthesia (coagulation disorder, infection at site of puncture, raised intracranial tension or any spine deformity), fever \\>38 Celsius or less than 36 Celsius, body mass index more than 35 and who has history of alcohol intake","21 Years","60 Years",{"count":233,"type":20},180,[150],"The aim of this work was to compare the efficacy of intravenous (IV) tramadol versus magnesium sulphate added to 100 ml saline for prevention of shivering associated with spinal anesthesia.",[237,238,26],"Lower Extremity Chronic Venous Ulcers","Varicose Veins Leg",[240,241,242],"Tramadol","Magnesium Sulphate","Shivering","2024-09-23",{"date":245,"type":42},"2024-09-25",{"date":247,"type":20},"2024-10-10",{"date":249,"type":20},"2025-01-10",{"name":251,"class":49},"Al-Azhar University",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":260,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":264,"conditions":265,"keywords":266,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":50},"100519150","patient-reported-outcomes-for-patients-undergoing-surgery-at-shouldice-hospital-100519150","NCT06039800","Patient-reported Outcomes for Patients Undergoing Surgery at Shouldice Hospital.","Patient Reported Outcome Measures (PROMS): Follow up of Shouldice Hospital Patients","PROM project","Inclusion Criteria:\n\n* All patients aged 16-90 who underwent hernia surgery at Shouldice Hospital are eligible.\n\nExclusion Criteria:\n\n* Lack of an email address.","16 Years",{"count":262,"type":20},2000,"OBSERVATIONAL","Background:\n\nPrevious publications have highlighted limited data on patient outcomes and experiences at Shouldice Hospital. Existing studies from Europe reported outcomes following Shouldice repair but lacked recent data. The current project seeks to optimize patient care and knowledge through systematic follow-up.\n\nStudy Objectives:\n\nEstablish a patient-reported outcome measure follow-up program. Evaluate postoperative complication rates. Determine important outcomes to patients. Establish and monitor patient satisfaction with decision-making and hernia repair.\n\nHypotheses\u002FResearch Questions:\n\nSeveral research questions related to patient motivations, outcomes, knowledge, and satisfaction are posed for investigation.\n\nPotential Risks and Benefits:\n\nNo anticipated risks to participants. Participants won't directly benefit but contribute to improving patient care and knowledge.\n\nStudy Design:\n\nThe study employs a prospective follow-up approach. Surveys are sent at specific intervals (30-40 days, 1-year, 3-years, and 5-years) via email.\n\nConsent forms are included in the email, allowing participants to choose their level of involvement. Data is collected from survey responses, patient charts, and operative notes.\n\nStudy Population:\n\nAll patients aged 16-90 who underwent hernia surgery at Shouldice Hospital are eligible.\n\nExclusion criteria:\n\nLack of an email address. The required sample size is unknown, and this study serves as a pilot.\n\nData Collection:\n\nData is collected from surveys, patient charts, and operative notes. Consent is obtained through deferred consent (initial contact via email, with consent forms provided).\n\nSafeguards are in place to protect personal health information.\n\nDuration of Study:\n\nEstimated to take 5-6 years. Recruitment\u002Fenrollment: 6-12 months. Follow-up: 5 years from the last enrolled participant. Data analysis and write-up: 5 months.\n\nOverlap with Other Projects:\n\nConcerns about overlap with other studies are addressed, and concurrent participation is allowed. Participants can withdraw at any time.\n\nIn summary, this research project aims to gather comprehensive data on hernia surgery outcomes, patient experiences, and satisfaction at Shouldice Hospital through a systematic follow-up approach, contributing to the improvement of patient care and knowledge in this field.",[26],[34,267],"groin hernia","2023-09-08",{"date":270,"type":42},"2023-09-15",{"date":272,"type":42},"2023-08-01",{"date":274,"type":20},"2028-08",{"name":276,"class":49},"Shouldice Hospital",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":182,"enrollmentInfo":284,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":50},"100360424","samples-procurement-for-colorectal-cancer-gastric-cancer-and-non-malignant-disease-100360424","NCT03972956","Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease","Samples Procurement for Patients With Colorectal Cancer, Gastric Cancer, and Non-malignant Disease Undergoing Surgery","Inclusion Criteria:\n\n* Any patient diagnosed with colorectal cancer, gastric cancer, non-malignant disease that requires undergoing surgery.\n* Must be willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Subjects whose comorbidities would preclude diagnostic or therapeutic intervention.",{"count":285,"type":20},1000,"The purposes of this study are to collect and store samples including blood, normal and tumor tissue from patients with colorectal cancer or gastric cancer, to collect and store samples including blood and\u002For normal gastrointestinal tissue (if available) from patients with non-malignant disease (including, but not limited to, inflammatory bowel disease (IBD), gastric ulcer, hemorrhoids or hernia), and to create a database for the collected samples and allow access to relevant clinical information for current and future protocols.",[288,289,290,291,292,26],"Colorectal Cancer","Gastric Cancer","Inflammatory Bowel Diseases","Gastric Ulcer","Hemorrhoids","2022-04-28",{"date":295,"type":42},"2022-04-29",{"date":297,"type":42},"2020-12-23",{"date":299,"type":20},"2026-12-23",{"name":301,"class":49},"Renmin Hospital of Wuhan University"]